Safety of perioperative hyperthermic intraperitoneal chemotherapy with gemcitabine in patients with resected pancreatic adenocarcinoma: a pilot study of the clinical trial EudraCT 2016-004298-41-Reference-Cited by-同舟云学术

Safety of perioperative hyperthermic intraperitoneal chemotherapy with gemcitabine in patients with resected pancreatic adenocarcinoma: a pilot study of the clinical trial EudraCT 2016-004298-41

Published:2021-04 Issue:S1 Volume:12 Page:S80-S90
ISSN:2078-6891
Container-title:Journal of Gastrointestinal Oncology
language:
Short-container-title:J Gastrointest Oncol

Author:

Padilla-Valverde David,García-Santos Esther,Sanchez Susana,Manzanares Carmen,Rodriguez Marta,González Lucia,Ambrós Alfonso,Cano Juana M.,Serrano Leticia,Bodoque Raquel,Vergara Teresa,Martin Jesus

Publisher

AME Publishing Company

Subject

Gastroenterology,Oncology

Link

https://jgo.amegroups.com/article/download/48473/pdf

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Effectiveness of Perioperative Hyperthermic Intraperitoneal Chemotherapy with Gemcitabine in Patients with Resected Pancreatic Ductal Adenocarcinoma: Clinical Trial EudraCT 2016-004298-41;Cancers;2024-04-28

2. Long-term recurrence-free survival following pancreatic surgery with HIPEC treatment for locally advanced pancreatic adenocarcinoma;BMJ Case Reports;2024-02

3. PIPAC for Gastrointestinal Malignancies;Journal of Clinical Medicine;2023-10-27

4. Preclinical safety study of a gemcitabine-controlled release polymer for locoregional administration in pancreatic cancer;Journal of Drug Delivery Science and Technology;2023-09

5. Hyperthermic intraperitoneal chemotherapy for management of gastrointestinal and biliary tract malignancies: a systematic review and meta-analysis of randomized trials;ANN GASTROENTEROL;2023